1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. RAD51

RAD51

RAD51, an essential eukaryotic DNA recombinase, promotes homologous pairing and strand exchange during homologous recombination (HR) and the recombinational repair of double strand breaks. RAD51 protein is recruited onto the DNA break by BRCA2 and forms homopolymeric filaments that invade the homologous chromatid and use it as a template for repair. RAD51 filaments are detectable by immunofluorescence as distinct foci in the cell nucleus, and their presence is a read out of HR proficiency. RAD51 is an essential gene, protecting cells from genetic instability.

RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukaemia (CML). Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been proposed as an alternative and supplementary strategy for cancer treatment.

RAD51 Related Products (19):

Cat. No. Product Name Effect Purity
  • HY-101462
    RAD51 Inhibitor B02
    Inhibitor 99.80%
    RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM.
  • HY-15317
    RI-1
    Inhibitor 99.83%
    RI-1 is a RAD51 inhibitor, with IC50s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells.
  • HY-19793
    RS-1
    Activator 98.95%
    RS-1 is a RAD51 activator, and also increases CRISPR/Cas9-mediated knock-in efficiencies.
  • HY-10206
    Amuvatinib
    Inhibitor 98.07%
    Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.
  • HY-126020
    Bractoppin
    Inhibitor 99.18%
    Bractoppin is a potent and selective drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem(t) BRCT domain (binding IC50: 74 nM). Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. Bractoppin preferentially inhibits BRCA1 tBRCT-dependent steps in the DNA damage response.
  • HY-150147
    CAM833
    Inhibitor 99.79%
    CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and RAD51 with a Kd of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization.
  • HY-148183
    Homologous recombination-IN-1
    Inhibitor
    Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC50=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination.
  • HY-143736
    RAD51-IN-5
    Inhibitor 98.87%
    RAD51-IN-5 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-5 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 3).
  • HY-103710
    IBR2
    Inhibitor 98.60%
    IBR2 is a potent and specific RAD51 inhibitor and inhibits RAD51-mediated DNA double-strand break repair. IBR2 disrupts RAD51 multimerization, accelerates proteasome-mediated RAD51 protein degradation, inhibits cancer cell growth and induces apoptosis.
  • HY-16904
    RI-2
    Inhibitor 99.64%
    RI-2 is a reversible RAD51 inhibitor, with an IC50 of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.
  • HY-122705
    RAD51-IN-1
    Inhibitor 99.97%
    RAD51-IN-1, a derivative of  B02, is a potent inhibitor of RAD51. RAD51-IN-1 can be used for cancer research.
  • HY-111887
    RAD51-IN-2
    Inhibitor 99.79%
    RAD51-IN-2 (compound example 67A) is a RAD51 inhibitor extracted from patent WO2019/051465A1.
  • HY-126972A
    RI(dl)-2 TFA
    Inhibitor ≥98.0%
    RI(dl)-2 TFA is a potent and selective RAD51-mediated D-loop formation inhibitor with an IC50 of 11.1 μM. RI(dl)-2 TFA does not influence RAD51 binding to ssDNA and inhibits homologous recombination (HR) activity in human cells (IC50 of 3.0 μM).
  • HY-136604
    RAD51-IN-3
    Inhibitor
    RAD51-IN-3 is a Rad51 inhibitor extracted from patent WO2019051465A1, compound Example 66A.
  • HY-143735
    RAD51-IN-4
    Inhibitor
    RAD51-IN-4 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-4 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2019014315A1, compound R12).
  • HY-143741
    RAD51-IN-7
    Inhibitor
    RAD51-IN-7 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-7 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 71).
  • HY-10206A
    Amuvatinib hydrochloride
    Inhibitor
    Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.
  • HY-143737
    RAD51-IN-6
    Inhibitor
    RAD51-IN-6 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-6 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 23).
  • HY-150958
    RAD51-IN-8
    RAD51-IN-8, a new RAD51 binder, is a RAD51-BRCA2 inhibitor that inhibits the RAD51 BRCA2 protein protein interaction. RAD51-IN-8 also is a protein−protein interaction (PPI) inhibitor. RAD51-IN-8 has inhibitory activity for H4A4 with an EC50 value of 19 μM.